Alexion Pharmaceuticals Inc. (ALXN) Stock Rating Reaffirmed by FBR & Co
Alexion Pharmaceuticals Inc. (NASDAQ:ALXN)‘s stock had its “sell” rating reaffirmed by research analysts at FBR & Co in a research report issued to clients and investors on Friday.
A number of other research analysts have also commented on the stock. Brean Capital began coverage on shares of Alexion Pharmaceuticals in a research report on Tuesday. They set a “buy” rating and a $221.00 price objective for the company. Vetr raised shares of Alexion Pharmaceuticals from a “strong sell” rating to a “sell” rating and set a $107.00 price objective for the company in a research report on Thursday, September 29th. Zacks Investment Research raised shares of Alexion Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, September 27th. Leerink Swann upped their price objective on shares of Alexion Pharmaceuticals from $210.00 to $211.00 and gave the company an “outperform” rating in a research report on Monday, September 26th. Finally, Jefferies Group cut their price objective on shares of Alexion Pharmaceuticals from $140.00 to $120.00 and set a “hold” rating for the company in a research report on Friday, September 23rd. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $178.32.
Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) traded up 1.76% during trading on Friday, hitting $125.05. The stock had a trading volume of 1,009,863 shares. The stock’s 50-day moving average price is $127.95 and its 200 day moving average price is $134.91. The stock has a market cap of $28.04 billion, a price-to-earnings ratio of 314.20 and a beta of 1.33. Alexion Pharmaceuticals has a one year low of $110.56 and a one year high of $193.45.
Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings data on Thursday, July 28th. The biopharmaceutical company reported $1.13 EPS for the quarter, missing the Zacks’ consensus estimate of $1.17 by $0.04. The company had revenue of $753 million for the quarter, compared to analyst estimates of $743.18 million. Alexion Pharmaceuticals had a net margin of 3.19% and a return on equity of 10.02%. The firm’s quarterly revenue was up 18.4% on a year-over-year basis. During the same period in the prior year, the company posted $1.44 EPS. On average, equities analysts forecast that Alexion Pharmaceuticals will post $4.67 EPS for the current year.
In related news, CEO David Hallal sold 332 shares of the firm’s stock in a transaction on Monday, August 8th. The shares were sold at an average price of $137.14, for a total transaction of $45,530.48. Following the sale, the chief executive officer now directly owns 189,266 shares in the company, valued at $25,955,939.24. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Alvin S. Parven sold 15,000 shares of the firm’s stock in a transaction on Monday, August 22nd. The stock was sold at an average price of $136.53, for a total transaction of $2,047,950.00. Following the sale, the director now owns 6,373 shares in the company, valued at $870,105.69. The disclosure for this sale can be found here. Insiders own 4.41% of the company’s stock.
Several large investors have recently modified their holdings of the company. Meeder Asset Management Inc. bought a new stake in shares of Alexion Pharmaceuticals during the first quarter worth approximately $114,000. NEXT Financial Group Inc raised its stake in shares of Alexion Pharmaceuticals by 66.1% in the second quarter. NEXT Financial Group Inc now owns 1,106 shares of the biopharmaceutical company’s stock worth $129,000 after buying an additional 440 shares during the last quarter. Bellwether Investment Group LLC bought a new stake in shares of Alexion Pharmaceuticals during the second quarter worth approximately $172,000. Charlemagne Capital Ltd. bought a new stake in shares of Alexion Pharmaceuticals during the second quarter worth approximately $191,000. Finally, Evercore Wealth Management LLC raised its stake in shares of Alexion Pharmaceuticals by 5.0% in the second quarter. Evercore Wealth Management LLC now owns 1,735 shares of the biopharmaceutical company’s stock worth $203,000 after buying an additional 83 shares during the last quarter. Institutional investors and hedge funds own 96.34% of the company’s stock.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).
Receive News & Stock Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.